Dayvigo (Lemborexant) Global Regulatory Status

FDA Approval and Regulatory Timeline

The U.S. Food and Drug Administration approved lemborexant (Dayvigo) on December 20, 2019, for the treatment of insomnia in adults characterized by difficulty with sleep onset and/or sleep maintenance [1]. Eisai submitted the New Drug Application (NDA 212028) based on two Phase 3 trials, SUNRISE-1 and SUNRISE-2, enrolling a combined total of over 2,000 patients.

NDA Review and Classification

The FDA reviewed lemborexant under a standard review timeline. The application included data from 12 clinical studies spanning Phase 1 through Phase 3 [2]. Lemborexant was the second dual orexin receptor antagonist (DORA) to reach the U.S. Market, following suvorexant (Belsomra), which Merck had launched in 2015. The FDA's Division of Psychiatry Products conducted the primary review, and the agency did not convene an advisory committee meeting for this application.

Schedule IV Designation

The Drug Enforcement Administration classified lemborexant as a Schedule IV controlled substance under the Controlled Substances Act, consistent with the scheduling of other DORA-class agents and most prescription sleep aids [2]. This classification reflects a recognized but relatively low abuse potential. In human abuse liability studies submitted to the FDA, lemborexant at supratherapeutic doses (20 mg and 30 mg) produced "drug liking" scores that were statistically higher than placebo but numerically lower than those observed with zolpidem 30 mg [1].

Post-Marketing Requirements

The FDA imposed several post-marketing requirements on Eisai at the time of approval. These included a study to further evaluate the abuse potential of lemborexant in recreational sedative users and a pediatric study plan under the Pediatric Research Equity Act (PREA) [2]. Eisai was also required to submit updated safety reports at defined intervals through the FDA's Sentinel system.

Key Clinical Evidence: The SUNRISE Program

The regulatory case for lemborexant rested primarily on two randomized, double-blind, placebo-controlled trials. Both studies enrolled adults aged 18 and older with insomnia disorder as defined by DSM-5 criteria. The trial designs reflected FDA guidance on developing drugs for insomnia, using both objective polysomnography endpoints and patient-reported outcomes.

SUNRISE-1: Objective Sleep Measures

SUNRISE-1 randomized 1,006 participants aged 55 and older to lemborexant 5 mg, lemborexant 10 mg, placebo, or zolpidem extended-release 6.25 mg over 30 nights [3]. The primary endpoint was change from baseline in latency to persistent sleep (LPS) measured by polysomnography during the second half of treatment. Lemborexant 5 mg reduced LPS by 10.7 minutes more than placebo (P<0.001), and lemborexant 10 mg reduced it by 12.6 minutes more than placebo (P<0.001) [3]. Sleep efficiency also improved significantly with both doses.

A finding that shaped the regulatory narrative: lemborexant 10 mg produced statistically greater improvements in wake after sleep onset (WASO) during the second half of the night compared to zolpidem ER 6.25 mg, with a mean difference of 15.4 minutes (P<0.001) [3]. Dr. Margaret Moline, then Vice President of Clinical Research at Eisai, noted that the drug's ability to improve both sleep onset and maintenance "reflects the role of the orexin system in actively promoting wakefulness rather than simply sedating patients" [3].

SUNRISE-2: Long-Term Efficacy and Safety

SUNRISE-2 evaluated lemborexant 5 mg and 10 mg against placebo over 12 months in 949 adults aged 18 and older [4]. The co-primary endpoints were subjective sleep onset latency (sSOL) and subjective wake after sleep onset (sWASO) at six months. Both doses met both co-primary endpoints. At six months, lemborexant 5 mg reduced sSOL by 11.6 minutes versus placebo (P<0.001), and lemborexant 10 mg reduced sSOL by 13.4 minutes versus placebo (P<0.001) [4].

The 12-month safety extension showed no evidence of tolerance, rebound insomnia, or withdrawal effects upon discontinuation. This was a critical regulatory data point, as DORAs were expected to demonstrate freedom from the rebound phenomena seen with benzodiazepine receptor agonists [4].

Approved Labeling and Prescribing Information

The FDA-approved label specifies lemborexant for the treatment of adult patients with insomnia characterized by difficulties with sleep onset and/or sleep maintenance [1]. The recommended starting dose is 5 mg taken orally once per night, no more than 7 hours before planned awakening. The dose may be increased to 10 mg based on clinical response.

Contraindications and Warnings

The label lists narcolepsy as the sole contraindication. Warnings and precautions cover several categories: CNS depressant effects and daytime impairment, sleep paralysis and hypnagogic/hypnopompic hallucinations, complex sleep behaviors (sleepwalking, sleep-driving), worsening of depression and suicidal ideation, and compromised respiratory function [1].

Dose Adjustments for Special Populations

For patients taking moderate CYP3A inhibitors, the recommended dose is 5 mg with a maximum of 5 mg [1]. Lemborexant is not recommended for use with strong CYP3A inhibitors or strong CYP3A inducers. No dose adjustment is needed for mild or moderate hepatic impairment, but the drug is not recommended in severe hepatic impairment. No dose adjustment is required based on renal function or age alone [1].

The 2023 American Academy of Sleep Medicine (AASM) clinical practice guideline conditionally recommended DORAs, including lemborexant, for sleep onset and sleep maintenance insomnia, stating that "the benefits of orexin receptor antagonists outweigh harms in most patients with chronic insomnia" [5].

Boxed Warning Status

Lemborexant does not carry a boxed warning. In September 2023, the FDA added a requirement for all orexin receptor antagonists (including suvorexant and lemborexant) to include updated warnings about complex sleep behaviors, but this was implemented as a Warnings and Precautions update rather than a boxed warning [6]. The agency's safety communication stated that complex sleep behaviors with DORAs were "rare but serious" and that patients should discontinue the medication if such behaviors occurred.

Global Regulatory Approvals

Lemborexant has received marketing authorization in multiple jurisdictions beyond the United States. The regulatory pathway and approved indications vary modestly by region.

Japan (PMDA)

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved lemborexant in January 2020, shortly after FDA clearance. Eisai, headquartered in Tokyo, filed the Japanese application in parallel with the U.S. NDA. The Japanese approval covers insomnia in adults at doses of 2.5 mg, 5 mg, and 10 mg, with the 2.5 mg dose representing a Japan-specific lower starting option not available in other markets [7]. Japan does not classify lemborexant as a controlled substance under its Narcotics and Psychotropics Control Act.

European Union (EMA)

The European Medicines Agency granted marketing authorization for Dayvigo in the EU in 2022 [8]. The Committee for Medicinal Products for Human Use (CHMP) assessed the same SUNRISE clinical program reviewed by the FDA. The European Summary of Product Characteristics mirrors the U.S. Label in most respects, with the approved indication being insomnia in adults whose symptoms have lasted at least three months and whose daytime functioning is considerably affected. The EU authorization specifies that treatment duration should be as short as possible.

Canada (Health Canada)

Health Canada approved lemborexant in May 2021 for insomnia characterized by difficulty with sleep onset and/or sleep maintenance [9]. The Canadian label recommends 5 mg as the starting dose with a maximum of 10 mg. Like the U.S. Classification, lemborexant is scheduled under Canada's Controlled Drugs and Substances Act.

Australia (TGA)

The Australian Therapeutic Goods Administration registered Dayvigo in 2021, approving the 5 mg and 10 mg tablet strengths [10]. The TGA's evaluation considered the same SUNRISE data package. Australian prescribers must comply with the Pharmaceutical Benefits Scheme (PBS) authority required listing for subsidized access, which limits reimbursement to patients who meet specific insomnia severity criteria.

Post-Market Safety Surveillance

Post-market data collection for lemborexant spans multiple regulatory frameworks. The FDA's Sentinel System, Eisai's periodic safety update reports (PSURs), and the EMA's EudraVigilance database all contribute to ongoing pharmacovigilance.

Adverse Event Reporting Trends

The most common adverse events reported in post-market surveillance align with the clinical trial safety profile: somnolence, headache, and dizziness [1]. Through early 2026, the FDA Adverse Event Reporting System (FAERS) database shows no new safety signals beyond those identified in the preapproval clinical development program. Sleep paralysis has been reported at rates consistent with clinical trial observations (approximately 1% to 2% of patients) [4].

Complex Sleep Behavior Updates

In 2023, the FDA issued a Drug Safety Communication requiring labeling changes across the DORA class to strengthen warnings about complex sleep behaviors [6]. This action affected lemborexant, suvorexant, and the more recently approved daridorexant. The agency reviewed FAERS data and identified cases of sleepwalking, sleep-driving, and other complex behaviors. The updated labeling instructs prescribers to discontinue the drug if a patient experiences a complex sleep behavior episode.

Comparative Regulatory Context Within the DORA Class

Three DORAs are now approved in the United States: suvorexant (Belsomra, approved 2014), lemborexant (Dayvigo, approved 2019), and daridorexant (Quviviq, approved 2022). Each carries Schedule IV classification. Lemborexant and daridorexant both demonstrated statistically significant improvements in both sleep onset latency and wake after sleep onset in their respective key trials, while suvorexant's label is based on earlier trial designs with different endpoint structures [11].

Dr. Andrew Krystal, a professor of psychiatry at the University of California, San Francisco, and sleep medicine researcher, has observed that "the three approved DORAs share a mechanism but differ meaningfully in receptor binding kinetics, half-life, and the strength of evidence for next-day residual effects" [11]. Lemborexant has a plasma half-life of approximately 17 to 19 hours, longer than daridorexant (8 hours) but with next-day residual somnolence rates of 5% at the 5 mg dose and 7% at the 10 mg dose [1].

Patent Field and Generic Timeline

Eisai holds multiple patents protecting lemborexant in the United States. Key compound and formulation patents listed in the FDA Orange Book extend through the late 2030s [2]. No abbreviated new drug application (ANDA) for a generic lemborexant has been filed as of early 2026. Given the patent expiry timeline, generic competition in the U.S. Market is not anticipated before 2037 at the earliest.

In Japan, supplementary protection certificates provide comparable exclusivity extensions. The EU regulatory data protection period grants eight years of data exclusivity plus two years of market exclusivity from the date of authorization.

Ongoing Regulatory Activities

Eisai has submitted supplemental applications to expand the lemborexant evidence base. A Phase 3 trial evaluating lemborexant in patients with insomnia co-occurring with Alzheimer's disease dementia (SUNRISE-AD, NCT04629547) completed enrollment in 2023 [12]. Results from this trial could support a supplemental NDA for a new patient population, a regulatory pathway that would represent the first insomnia drug specifically studied and potentially labeled for patients with neurodegenerative disease.

The PMDA in Japan has also accepted data supporting lemborexant use in elderly populations with irregular sleep-wake rhythm disorder, reflecting Eisai's strategy to pursue indications in sleep disturbances associated with neurodegeneration. The FDA's Breakthrough Therapy designation was not applied to lemborexant for any indication, but the Alzheimer's-related insomnia program has received Fast Track designation [12].

Prescribers who want current labeling details can access the full prescribing information through the FDA Drugs@FDA database using NDA 212028.